Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MC4R | P32245 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20399168 | 1.00 | KMT2A (0.47) | KMT2AMEN1KDM4ETP53RECQL | |
| SCHEMBL23130574 | 0.93 | KDM4E (0.44) | KMT2AMEN1KDM4ETP53RECQL | |
| SCHEMBL10088096 | 0.91 | RECQL (0.42) | KMT2AMEN1KDM4ERECQLALDH1A1 | |
| SCHEMBL11598889 | 0.91 | RECQL (0.42) | KMT2AMEN1KDM4ERECQLALDH1A1 | |
| Hydrochloric Acid SCHEMBL23522369 | 0.91 | KMT2A (0.45) | KMT2AMEN1KDM4ETP53RECQL | |
| SCHEMBL5627160 | 0.83 | ALDH1A1 (0.46) | KMT2AMEN1KDM4ERECQLALDH1A1 | |
| SCHEMBL2011908 | 0.81 | ALDH1A1 (0.49) | KMT2AMEN1KDM4ETP53ALDH1A1 | |
| SCHEMBL10941017 | 0.81 | ALDH1A1 (0.49) | KMT2AMEN1KDM4ETP53ALDH1A1 | |
| SCHEMBL16582348 | 0.81 | KMT2A (0.38) | KMT2AMEN1KDM4ESMN1; SMN2 | |
| SCHEMBL25227399 | 0.80 | KMT2A (0.38) | KMT2AMEN1KDM4ETP53RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028329-A1 | JAK1 SELECTIVE INHIBITORS | ASTRAZENECA AB (SE) | 2026-01-29 | — | — | US | disclosed |
| US-12473272-B2 | JAK1 selective inhibitors | ASTRAZENECA AB (SE) | 2025-11-18 | — | — | US | disclosed |
| US-20240208947-A1 | JAK1 SELECTIVE INHIBITORS | ASTRAZENECA AB (SE) | 2024-06-27 | — | — | US | disclosed |
| US-11897869-B2 | JAK1 selective inhibitors | ASTAZENECA AB (SE) | 2024-02-13 | — | — | US | disclosed |
| WO-2023178299-A1 | PRODRUGS OF GANAXOLONE | MARINUS PHARMACEUTICALS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| EP-4219470-A1 | JAK1 SELECTIVE INHIBITORS | Astrazeneca AB (SE) | 2023-08-02 | — | — | EP | disclosed |
| CN-115925693-A | Selective inhibitors of JAK1 | 阿斯利康(瑞典)有限公司 | 2023-04-07 | — | — | CN | disclosed |
| EP-3571192-B1 | JAK1 SELECTIVE INHIBITORS | ASTRAZENECA AB (SE) | 2022-11-30 | — | — | EP | disclosed |
| CN-110461830-B | Selective inhibitors of JAK1 | 阿斯利康(瑞典)有限公司 | 2022-11-01 | — | — | CN | disclosed |
| EP-3854793-A1 | AROMATIC HETEROCYCLIC COMPOUND WITH KINASE INHIBITORY ACTIVITY | Shanghai Ennovabio Pharmaceuticals Co., Ltd. (CN) | 2021-07-28 | — | — | EP | disclosed |
| US-20210188821-A1 | JAK1 SELECTIVE INHIBITORS | ASTRAZENECA PHARMACEUTICALS LP | 2021-06-24 | — | — | US | disclosed |
| US-10961228-B2 | JAK1 selective inhibitors | ASTRAZENECA AB (SE) | 2021-03-30 | — | — | US | disclosed |
| WO-2020057669-A1 | AROMATIC HETEROCYCLIC COMPOUND WITH KINASE INHIBITORY ACTIVITY | 上海轶诺药业有限公司 | 2020-03-26 | — | — | WO | disclosed |
| CN-110461830-A | Selective inhibitors of JAK1 | ASTRAZENECA AB | 2019-11-15 | — | — | CN | disclosed |
| WO-2018134213-A1 | JAK1 SELECTIVE INHIBITORS | ASTRAZENECA AB (SE) | 2018-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12473272-B2 | JAK1 selective inhibitors | JAK1, JAK2, JAK3 | KMT2A 982/4885MEN1 2067/4885KDM4E 1112/4885 |
| US-11897869-B2 | JAK1 selective inhibitors | JAK1, JAK2, JAK3 | KMT2A 982/4885MEN1 2067/4885KDM4E 1112/4885 |
| US-20260028329-A1 | JAK1 SELECTIVE INHIBITORS | JAK1, JAK2, JAK3 | KMT2A 323/4885MEN1 510/4885KDM4E 365/4885 |
| US-20240208947-A1 | JAK1 SELECTIVE INHIBITORS | JAK1, JAK2, JAK3 | KMT2A 982/4885MEN1 2067/4885KDM4E 1112/4885 |
| US-20210188821-A1 | JAK1 SELECTIVE INHIBITORS | JAK1, JAK2, JAK3 | KMT2A 982/4885MEN1 2067/4885KDM4E 1112/4885 |
| US-10961228-B2 | JAK1 selective inhibitors | JAK1, JAK2, JAK3 | KMT2A 982/4885MEN1 2067/4885KDM4E 1112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.